| خلاصه مقاله | Over the past two decades, stem cell- based therapies have been extensively applied for a variety of
challenging diseases and pathological conditions, especially cardiovascular diseases (CVDs). Stem cells
are capable of replacing damaged cells and organ regeneration. Emerging studies have proven the
therapeutic value of stem cell exosomes (Exos) for cardiac tissue repair and regeneration. It is believed
that mesenchymal stem cell (MSC) Exos are potential alternatives to whole- cell therapy because they
mimic the biological activity of MSCs. Exosomal cargos could diminish cardiomyocyte apoptosis, and
induce cardiomyocyte proliferation, leading to the restoration of injured myocardium after several
pathologies. Besides, these Exos recover cardiac function by modulation of inflammatory biomarkers
such as CD68. Data have indicated that miR-146a-modified adipose- derived stem cells (ADSCs) Exos
can inhibit the release of proinflammatory cytokines and thus reduce further myocardial damage. Exos
from other stem cell sources such as cardiac progenitor cells (CPC) exert regenerative potential by
providing signal molecules into the cardiac microenvironment. Therefore, CPCs-Exos can contribute to
cardiac tissue homeostasis under pathological conditions.
Therefore, stem cell Exos seems to be the potential magic bullet to promote cardiac repair and
regeneration following various CVDs. Furthermore, the development of novel theranostic methods in
terms of Exos provides a great tool for in-time diagnosis and therapeutic interventions in CVD patients.
However, the use of Exos for cardiac repair is still in its infancy, and further clinical studies in this context
are mandatory |